ATE337011T1 - Modifizierte psma-liganden und deren verwendung - Google Patents

Modifizierte psma-liganden und deren verwendung

Info

Publication number
ATE337011T1
ATE337011T1 AT02761082T AT02761082T ATE337011T1 AT E337011 T1 ATE337011 T1 AT E337011T1 AT 02761082 T AT02761082 T AT 02761082T AT 02761082 T AT02761082 T AT 02761082T AT E337011 T1 ATE337011 T1 AT E337011T1
Authority
AT
Austria
Prior art keywords
psma ligands
modified psma
diagnosis
detection
treatment
Prior art date
Application number
AT02761082T
Other languages
English (en)
Inventor
John V Frangioni
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE337011T1 publication Critical patent/ATE337011T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/005—Compounds of elements of Group 5 of the Periodic Table without metal-carbon linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6596—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02761082T 2001-02-07 2002-02-07 Modifizierte psma-liganden und deren verwendung ATE337011T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26705501P 2001-02-07 2001-02-07

Publications (1)

Publication Number Publication Date
ATE337011T1 true ATE337011T1 (de) 2006-09-15

Family

ID=23017130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761082T ATE337011T1 (de) 2001-02-07 2002-02-07 Modifizierte psma-liganden und deren verwendung

Country Status (8)

Country Link
US (4) US6875886B2 (de)
EP (1) EP1363920B1 (de)
JP (1) JP2005507857A (de)
AT (1) ATE337011T1 (de)
CA (1) CA2436408A1 (de)
DE (1) DE60214134T2 (de)
MX (1) MXPA03007037A (de)
WO (1) WO2002098885A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20090098046A1 (en) * 2005-01-14 2009-04-16 Michael Becker Combination Cancer Therapy with Anti-PSMA Antibodies
JP2008535865A (ja) * 2005-04-08 2008-09-04 サイトジェン コーポレーション 抗ｐｓｍａコンジュゲート抗体
US20060264414A1 (en) * 2005-04-08 2006-11-23 The Board of Regents, University and Community College System of Nevada on behalf of the Fluorous 2,2'-bipyridines and fluorinated biphasic sysems for ligand design
WO2006121920A2 (en) * 2005-05-05 2006-11-16 Beth Israel Deaconess Medical Center, Inc. Micro-scale resonant devices and methods of use
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
CA2626435A1 (en) * 2005-10-18 2007-05-10 Centre National De La Recherche Scientifique (Cnrs) Hypophosphorous acid derivatives and their therapeutical applications
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
JP2009532338A (ja) * 2006-03-14 2009-09-10 キャンサー ターゲテッド テクノロジー エルエルシー Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法
EP2007435B1 (de) * 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System zur gezielten verabreichung von heilmitteln
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US7993927B2 (en) 2006-07-03 2011-08-09 Beth Israel Deaconess Medical Center, Inc. Histology methods
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20110033379A1 (en) * 2006-08-29 2011-02-10 Frangioni John V Radio-labeled materials and methods of making and using the same
CA2668197A1 (en) * 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CN104774175B (zh) 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
US20100137258A1 (en) * 2007-08-01 2010-06-03 Francine Acher Thiophosphi(o)nic acid derivatives and their therapeutical applications
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
FR2920086A1 (fr) 2007-08-24 2009-02-27 Univ Grenoble 1 Systeme et procede d'analyse pour une operation chirurgicale par endoscopie
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
EP3424525A1 (de) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Impfstoffnanotechnologie
ES2765240T3 (es) 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
ES2776126T3 (es) * 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
JP5798043B2 (ja) 2009-02-06 2015-10-21 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド 電荷均衡造影剤
US10493169B2 (en) 2009-02-06 2019-12-03 Beth Israel Deaconess Medical Center Use of charge-balanced imaging agents for determining renal function
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
WO2011072218A2 (en) 2009-12-11 2011-06-16 Bind Biosciences Stable formulations for lyophilizing therapeutic particles
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
ME03353B (de) 2011-03-29 2019-10-20 Immunogen Inc Herstellung von maytansinoid-antikörperkonjugaten anhand eines einstufigen verfahrens
EP2817629A4 (de) * 2012-02-24 2016-01-13 Univ Cornell Erhöhter psma-wert als identifikator von tödlichem prostatakrebs
CA2865774A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
PT2895156T (pt) 2012-09-17 2019-06-28 Pfizer Processo para a preparação de nanopartículas terapêuticas
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
MY171561A (en) 2012-11-15 2019-10-18 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
JP6192799B2 (ja) 2013-03-15 2017-09-06 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物
US20170232119A1 (en) 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
EP2842578B1 (de) * 2013-08-27 2018-06-27 GILUPI GmbH Diagnosevorrichtung zum nachweis von biomarkern
GEP20237479B (en) 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3069147A4 (de) 2013-11-14 2017-10-11 Endocyte, Inc. Verbindungen für positronenemissionstomografie
SI3116547T1 (sl) 2014-03-14 2019-08-30 Pfizer, Inc. Terapevtski nanodelci, ki obsegajo terapevtsko stredstvo, in postopek izdelave ter uporabe le-teh
US9956305B2 (en) * 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
SG11202010217YA (en) 2018-04-17 2020-11-27 Endocyte Inc Methods of treating cancer
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN120282804A (zh) 2022-09-23 2025-07-08 核素迪姆股份公司 高纯度铜放射性药物组合物及其诊断和治疗用途
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4204642B2 (ja) 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺に特異的な膜抗原
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
HUP9903421A3 (en) 1996-06-17 2001-08-28 Guilford Pharmaceuticals Inc B Use of phosphonic and phosphinic acid derivatives for producing pharmaceutical compositions having naaladase inhibitor activity
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6025345A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
KR20000036227A (ko) 1996-09-27 2000-06-26 토마스 씨. 서 날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6444657B1 (en) * 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6348464B1 (en) 1999-11-12 2002-02-19 Guilford Pharmaceuticals, Inc. Pyrrolecarbonylimino derivatives as naaladase inhibitors
US7254409B2 (en) * 2000-04-14 2007-08-07 Ntt Docomo, Inc. Multicast service providing system, multicast service providing method, information distributor, radio terminal, and radio base station
WO2001092273A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
US6687498B2 (en) * 2000-08-14 2004-02-03 Vesuvius Inc. Communique system with noncontiguous communique coverage areas in cellular communication networks
US6954641B2 (en) * 2000-08-14 2005-10-11 Vesivius, Inc. Communique wireless subscriber device for a cellular communication network
US6594498B1 (en) * 2000-08-14 2003-07-15 Vesuvius, Inc. Communique system for cellular communication networks
US6907023B2 (en) * 2000-08-14 2005-06-14 Vesuvius, Inc. Communique system with dynamic bandwidth allocation in cellular communication networks
US6684076B2 (en) * 2000-08-14 2004-01-27 Vesuvius Inc. Communique system with hierarchical communique coverage areas in cellular communication networks
US6741856B2 (en) * 2000-08-14 2004-05-25 Vesuvius Inc. Communique system for virtual private narrowcasts in cellular communication networks
US6829486B2 (en) * 2000-08-14 2004-12-07 Vesuvius Communique system for combined cellular and wireline communication networks
US6681115B1 (en) * 2000-08-14 2004-01-20 Vesuvius Inc. Communique subscriber handoff between a narrowcast cellular communication network and a point-to-point cellular communication network
US7024200B2 (en) * 2000-08-14 2006-04-04 Vesuvius, Inc. Communique system with active feedback for cellular communication networks
WO2002038190A2 (en) * 2000-10-27 2002-05-16 Beth Israel Deaconess Medical Center Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates
WO2002057222A2 (en) 2001-01-17 2002-07-25 Guilford Pharmaceuticals Inc. Thiol-based naaladase inhibitors

Also Published As

Publication number Publication date
JP2005507857A (ja) 2005-03-24
MXPA03007037A (es) 2003-11-18
US20040110723A1 (en) 2004-06-10
US6875886B2 (en) 2005-04-05
EP1363920B1 (de) 2006-08-23
CA2436408A1 (en) 2002-12-12
US20080175789A1 (en) 2008-07-24
EP1363920A1 (de) 2003-11-26
EP1363920A4 (de) 2004-04-21
DE60214134D1 (de) 2006-10-05
DE60214134T2 (de) 2007-07-19
US20050245486A1 (en) 2005-11-03
WO2002098885A1 (en) 2002-12-12
US20040229845A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
DE69936049D1 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2003033731A3 (en) Methods for detecting ovarian cancer
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
WO2004016160A3 (en) Redox polymer nanoparticles
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
DE60032784D1 (de) Markerproteine für prostatakrebs
WO2003093794A3 (en) Methods for discovering tumor biomarkers and diagnosing tumors
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
DE50205750D1 (de) Liganden für den nachweis von prionen
WO2008104805A3 (en) Proteins
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2003002765A3 (en) Methods for the diagnosis of cancer based on the obcam and ntm genes
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
WO2003024302A3 (en) Detection and treatment of cancers of breast
EA200600012A1 (ru) Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку
WO2002081640A3 (en) Gene shinc-1 and diagnostic and therapeutic uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties